Wilson disease combined with polycystic ovary syndrome–clinical features, treatment, and outcome in Chinese patients

• DOI: 10.1186/s12902-025-01899-z
• Publication Date: 2025-03-24T03:19:32Z
• Authors: Lin Chen; Ming-juan Fang; Liang-liang Zhang; Yong-feng Liu; Yong-zhu Han; Xu-en Yu; Yin Xu

We aimed to analyze the clinical features, treatment, and prognosis of Wilson disease (WD) combined with polycystic ovary syndrome (PCOS), explore correlation between endocrine abnormalities liver damage. The data 40 female patients WD PCOS (PCOS-WD) were retrospectively analyzed. 43 age- BMI-matched non-WD (PCOS-NWD) performed as control group. PCOS-WD assigned adolescent group (n = 18) reproductive age 22) according onset PCOS, also normal testosterone elevated level. laboratory tests, imaging examinations, outcome all analyzed, analysis was processed gonadal hormone damage parameters. level significantly higher in PCOS-NWD than (Z=-2.306, P 0.021). hyperandrogenism more prevalent within (P 0.025), while serum alanine aminotransferase (Z=-2.572, 0.010). hepatic fibrosis index (Z -2.190, 0.029), progesterone lower 2.394, 0.017). positively correlated 0.039, R 0.328). In followed-up observations, no significant difference found menstrual cycle pregnancy outcomes copper chelation therapy alone. is an important comorbidity patients. extent may be related hormonal imbalance PCOS. study recommends routine screening for Testosterone levels serve a valuable reference informing treatment decisions. Copper or without beneficial recovery PCOS-WD. 1. Contributing expanded understanding WD. 2. Emphasis comorbid 3. sample size limited, larger scale cohort studies are needed provide conclusive evidence. 4. large-sample multi-center observations standard dosage courses confirm plan future.